Corbion's Algae Omega-3 Catalyst and the Cost of the Middle East

Q2 organic sales accelerate 8.5% while margin guidance is trimmed on sulfuric acid inflation — a tale of two forces

CRBN.AS · Earnings Call · 2026-07-31

Acceleration in the Core

Corbion's second quarter delivered the step-change that management had been promising. “Organic sales grew 2.1% in the first half. And the important point is the acceleration in Q2, up 8.5% to EUR 337.4 million.” — Olivier Rigaud, CEO · 2026-07-31 Volume/mix was the primary driver, up 10.7% in the quarter, with pricing a modest drag. This was led by double-digit volume/mix growth across both Nutrition and Biomaterials in Omega 3 and by a strong rebound in Functional Ingredients & Solutions (FIS). The FIS segment saw sales growth of 8.4% in Q2, with margins sequentially up 250 bps. The food preservation platform continued to win on clean label and 3D printing-driven PLA demand — the latter clearly a global theme visible in the broader tape.

The Algae Omega-3 Story is Now Structurally Bullish

Management leaned heavily into the fish oil supply story. Olivier Rigaud framed it as a structural inflection:

Every quota reduction, every climate disruption, every tightening in fish oil supply reinforces the strategic value of Corbion's algae omega-3s.
Olivier Rigaud, CEO · 2026-07-31

Peru's reduced fishing quotas and the threat of el niño have pushed fish oil prices up more than 60% year-on-year — a tailwind that is already visible in the non-contracted portion of the business. Peter Kazius noted in Q&A that “we anticipate a significant price increase if you compare H2 this year versus H1 this year” — Peter Kazius, CFO · 2026-07-31 and that the majority of H2 order books are fixed. The longer-term contracted aquaculture contracts (roughly two-thirds of volumes) expire at end-2026, setting up a renegotiation window for 2027 at higher prices. This was already flagged in the prior call: “we have roughly 2/3 of our business that is on a longer-term contract... the others we are ending in '26.” — Olivier Rigaud, CEO · 2026-03-02 Now the negotiations are starting in earnest.

Middle East Cost Pressures vs. Margin Discipline

The bullish volume story is offset by a cost headwind that forced a margin guidance cut. The company refined its adjusted EBITDA margin outlook to "above 16%" from "around 17%." Peter Kazius explained: “It's predominantly driven by the Middle East... now we face a kind of gross bill of EUR 15 million to EUR 20 million, which is partly mitigated by cost disciplined actions and pricing, but not fully.” — Peter Kazius, CFO · 2026-07-31 This is a notable escalation from the prior quarter's estimate of up to EUR 10 million. The pressure is largely sulfuric acid costs, which rose further due to the sulfuric acid supply chain disruptions. However, management reiterated confidence in the H2 volume ramp and the free cash flow guidance of EUR 85–90 million, citing working capital normalization.

PLA Divestment and the Broader Portfolio

The process to sell the TotalEnergies Corbion joint venture continues. Management remained tight-lipped on timing but repeated that talks with prospective buyers are progressing. The JV's Q2 sales surged 44% organically, aided by strong Asian PLA demand, which supports the sales case. Olivier highlighted that the new gypsum-free lactic plant in Thailand provides a competitive advantage, especially now that sulfuric acid is expensive: “this is the only plant in the world with no sulfuric acid” — Olivier Rigaud, CEO · 2026-04-22 (from a prior call). This plant is ramping toward 100k tonnes capacity, and the PLA volume growth helps fill it.

What Changed and Why It Matters

The investment thesis for Corbion has bifurcated. The near-term margin is being squeezed by Middle East-driven input costs, but the structural opportunity in algae omega-3 has never been more favorably positioned. The Q2 volume acceleration across all segments, particularly in Health & Nutrition, validates the growth strategy. The renegotiation of long-term contracts in the second half of 2026 and into 2027 could be the pivotal event for 2027 earnings. As management put it, the market is now recognizing algae as a necessary solution, not just a viable alternative. This is a classic 'under-promise, over-deliver' setup if the pricing stickiness holds.